You need to enable JavaScript to run this app.
Recon: Boston Scientific buys urology devicemaker Axonics for $3.7 billion; J&J, Merck announce purchases of cancer therapy developers
Recon
Jason Scott
Global
ReconJason Scott
GlobalReconJason ScottGlobal